Glenmark Pharmaceuticals Ltd (GLEN)

BSE
Currency in INR
1,540.20
+42.00(+2.80%)
Closed
GLEN Scorecard
Full Analysis
High shareholder yield
Earnings results expected in 5 days
Fair Value
Day's Range
1,490.101,552.95
52 wk Range
766.651,830.05
Key Statistics
Edit
Bid/Ask
1,509.00 / 1,548.80
Prev. Close
1,498.2
Open
1,498.2
Day's Range
1,490.1-1,552.95
52 wk Range
766.65-1,830.05
Volume
15.85K
Average Volume (3m)
28.81K
1-Year Change
82.81%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GLEN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Glenmark Pharmaceuticals Ltd Company Profile

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company’s pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Employees
14989
Market
India

Compare GLEN to Peers and Sector

Metrics to compare
GLEN
Peers
Sector
Relationship
P/E Ratio
−42.7x34.6x−0.6x
PEG Ratio
0.051.560.00
Price/Book
5.1x5.9x2.6x
Price / LTM Sales
3.3x4.6x3.1x
Upside (Analyst Target)
15.5%14.8%47.1%
Fair Value Upside
Unlock−7.2%8.1%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -31.01
Dividend Yield
0.16%
Industry Median 0.70%
Annualised payout
2.5000
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Nov 14, 2024
EPS / Forecast
12.55 / 14.70
Revenue / Forecast
34.34B / 34.89B
EPS Revisions
Last 90 days

People Also Watch

386.80
BION
-2.56%
2,201.15
LUPN
+0.72%
1,383.25
VOLT
+2.33%
8,535.85
COFO
+0.17%
641.35
LAUL
+0.71%

FAQ

What Is the Glenmark Pharma (GLEN) Stock Price Today?

The Glenmark Pharma stock price today is 1,540.20

What Stock Exchange Does Glenmark Pharma Trade On?

Glenmark Pharma is listed and trades on the BSE stock exchange.

What Is the Stock Symbol for Glenmark Pharma?

The stock symbol for Glenmark Pharma is "GLEN."

Does Glenmark Pharma Pay Dividends? What’s The Current Dividend Yield?

The Glenmark Pharmaceuticals Ltd dividend yield is 0.16%.

What Is the Glenmark Pharma Market Cap?

As of today, Glenmark Pharma market cap is 434.61B.

What is Glenmark Pharma Earnings Per Share?

The Glenmark Pharma EPS is -31.01.

What Is the Next Glenmark Pharma Earnings Date?

Glenmark Pharma will release its next earnings report on 13 Feb 2025.

From a Technical Analysis Perspective, Is GLEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.